An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents

Methods in Molecular Biology

Volumn 928, Issue , 2012, Pages 175-184

  Azam, Mohammad ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acquired drug resistance; Protein kinase; Retroviral screening; Small molecule inhibitors; Tyrosine kinase inhibitors

Indexed keywords

EID: 84868598467     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-008-3_14     Document Type: Article

References (19)

1. Azam M, Daley GQ (2006) Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 10: 67-76
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70 (Pubitemid 30046295)
3. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-65 (Pubitemid 32467045)
4. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109: 275-82 (Pubitemid 34606870)
5. Melnikova I, Golden J (2004) Targeting protein kinases. Nat Rev Drug Discov 3: 993-4 (Pubitemid 39642356)
6. Cohen P (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-15 (Pubitemid 37361447)
7. Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296-313 (Pubitemid 37361688)
8. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-5 (Pubitemid 38374863)
9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympho-blastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-42 (Pubitemid 32267973)
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-6
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-80 (Pubitemid 32743979)
12. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-25 (Pubitemid 41039112)
13. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472-5 (Pubitemid 34525335)
14. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-43 (Pubitemid 36378885)
15. Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ (2006) Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 103: 9244-9 (Pubitemid 43902563)
16. Azam M, Powers JT, Einhorn W, Huang WS, Shakespeare WC, Zhu X, Dalgarno D, Clackson T, Sawyer TK, Daley GQ (2010) AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des 75: 223-7
17. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15: 1109-18
18. Azam M, Raz T, Nardi V, Opitz SL, Daley GQ (2003) A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online 5: 204-10 (Pubitemid 38097516)
19. Koh EY, Chen T, Daley GQ (2002) Novel ret-roviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res 30: e142